Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
PHILADELPHIA and OXFORD, United Kingdom, Feb. 03, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the following two conferences, both being held at the Waldorf Astoria in New York City:
- The 2016 BIO CEO & Investor Conference on Tuesday February 9, 2016 at 9:00AM ET (2:00 PM GMT); and
- The Leerink Partners 5th Annual Global Healthcare Conference on Wednesday February 10, at 8:25 AM ET (1:25 PM GMT).
Adaptimmune’s presentations will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: [email protected]
